Axonics, Inc.

NasdaqGS:AXNX Voorraadrapport

Marktkapitalisatie: US$3.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Axonics Beheer

Beheer criteriumcontroles 3/4

De CEO Axonics is Ray Cohen, benoemd in Oct2013, heeft een ambtstermijn van 11.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.37M, bestaande uit 10.9% salaris en 89.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.57% van de aandelen van het bedrijf, ter waarde $ 20.62M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7 jaar en 5.6 jaar.

Belangrijke informatie

Ray Cohen

Algemeen directeur

US$7.4m

Totale compensatie

Percentage CEO-salaris10.86%
Dienstverband CEO11.1yrs
Eigendom CEO0.6%
Management gemiddelde ambtstermijn7yrs
Gemiddelde ambtstermijn bestuur5.6yrs

Recente managementupdates

Recent updates

Seeking Alpha • Nov 05

Axonics' Market Growth Strengthens Boston Scientific's Future

Summary Boston Scientific Corporation plans to acquire Axonics, Inc. for $3.7 billion in cash to expand its urology offerings with Axonics' innovative urinary and bowel disorder treatments. Axonics, founded in 2013, is renowned for developing less invasive treatments for bladder and bowel issues, including a neurostimulator with a 20-year battery life. Boston Scientific, a major player in medical technology since 1979, will enhance its sacral neuromodulation capabilities through this acquisition. The acquisition positions Boston Scientific to better support individuals with chronic bladder and bowel conditions, strengthening its market presence in this growing field. Read the full article on Seeking Alpha
Analyseartikel • Jul 14

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Key Insights Axonics' estimated fair value is US$55.68 based on 2 Stage Free Cash Flow to Equity Current share price of...
Analyseartikel • Jun 20

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Axonics, Inc.'s ( NASDAQ:AXNX ) price-to-sales (or "P/S") ratio of 8.8x might make it look like a strong sell right now...
Analyseartikel • Mar 27

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Axonics fair value estimate is US$70.50 Current share price of...
Analyseartikel • Feb 28

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Nov 28

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Does the November share price for Axonics, Inc. ( NASDAQ:AXNX ) reflect what it's really worth? Today, we will estimate...
Seeking Alpha • Oct 10

Axonics stock falls 5.6% after Needham downgrades rating

Axonics (NASDAQ:AXNX) is trading 5.6% lower after Needham downgraded rating to hold from buy. The analyst Mike Matson sees a less favorable risk/reward profile after Needham's urologist survey suggested the company may have difficulty driving upside to consensus 2023 revenue estimates. Matson says Axonics F15 product cycle is now largely reflected in the shares, and no additional major product cycles are expected in the next 12-18 months. He believes the stock now appears to be fairly valued. AXNX is up 7.5% in the last 12 months.
Seeking Alpha • Sep 07

Axonics Stock Is A Buy Amid Current Capex Cycle

Summary Axonics looks well-positioned to continue its recent upside on the chart, with a number of idiosyncratic tailwinds yet to be recognized. The recent equity underwriting of $35mm is noted, although this is hardly a risk given intended use for capital initiatives. Shares are trading at a premium relative to peers within the sector, however, valuations are more appealing on a composite of measures. On the culmination of these factors, we rate AXNX a buy. Investment summary Considering the systematic drivers of equity returns are well at play (namely, macroeconomic drivers, rates, industry factors, and growth factors) in markets right now, we argue to seek out exposure to idiosyncratic risk premia in order to derive risk-adjusted alpha. With this front of mind, we rate Axonics, Inc. (AXNX) a speculative buy following Q2 results and additional market factors discussed below. The company's niche operating segment continues to offer a defensible growth play albeit with little correlation to equity markets, attractive features in the current investment landscape. In addition to these points, shares are trading at multiples above the peer median; however, this is balanced when factoring in a number of inputs into the valuation debate. With this, and recent momentum on the chart in mind, we rate AXNX a buy. Exhibit 1. AXNX 6-month price action Data: Refinitiv Eikon How current market factors impact AXNX The high-beta trade has unwound itself in FY22, and investors must now find selective opportunities with asymmetrical pricing within risk assets. Factor rotations have also been of high magnitude this year as well. Continuing its return to grace, value caught a strong bid from the June bounce, as seen in Exhibit 2. Investors have nibbled at compressed multiples in June-August as yields stabilized and a slight tightening of inflation. Value also continues to attract strategic positioning as managers seek to wind back equity duration and beta. Meanwhile, growth as caught a bid since this time as well, particularly in late August. This has direct implications to the outlook of the AXNX share price. With cash flows priced out into the future, we need investors to be net buyers of growth - and pay a premium at that to capture market-derived alpha when looking ahead. Exhibit 2. Both growth and value have caught a bid since the June bounce, highlighting some return in confidence to equities Data: Updata Meanwhile, whist yields have rolled over in recent months, alongside stock/bond correlations, a recent spike in the VIX and the long-end suggests stocks may not be out of the water, and raises questions on the validity of the relief rally outlined above. Exhibit 3. Whilst stock/bond correlations and yields have rolled over in recent months, recent spikes in volatility in stocks and steepness at the long-end suggest we aren't out of the woods at all Data: Updata Q2 earnings conducive of growth play AXNX generated total revenue of $69 million ("mm") last quarter, a 50% YoY growth schedule. Upside was driven by sacral neuromodulation ("SNM") revenue of $55.8mm, a 39% YoY gain. Nearly 100% of turnover was generated in the US, mitigating FOREX headwinds (although, the company did recognize a $12mm non-cash forex adjustment in its comprehensive loss). Q2 SNM sales were propped by the launch of the recharge-free Axonics F15 system. Meanwhile, Bulkamid sales came in at ~$13mm with ~$3mm in ex-US revenue, as the speed of new accounts and volume from existing accounts both saw upticks. We estimate the Bulkamid transaction (completed February FY21) to be accretive to ~$0.18 (18% margin) in EPS during the quarter. From the increase in revenue volume, gross margin increased by ~10 percentage points YoY to 72.8%. Moving down the P&L, it bought this down to an operating loss of ~$21.4mm, as operating expense came in 60% higher YoY. Net loss narrowed to ~$21mm, with a $12mm expense for foreign currency translation adjustments, bringing the comprehensive loss to $34mm. The strong quarter sees management lift FY22 guidance to 40% in revenue growth, calling for $253mm at the topline (previously $238mm). It anticipates SNM revenue of ~$205mm and Bulkamid to contribute $48mm, a 111% YoY gain. With respect to CMS outpatient facility rates, for 2023, the relevant sacral neuromodulation codes proposed an increase of 5-7%, whereas the Bulkamid code an increase of ~4%. In terms of catalysts to move the needle, we estimate there is substantial premium yet to be priced in by the market with regards to the company's 4th generation neurostimulator. AXNX submitted its PMA supplement to the FDA back in May on this. Key changes to the current model are around recharging, in that, the new model will only need recharging every 6 months for 1 hour, down from once a month. It expects this to be approved by year's end. AXNX valuation and conclusion Shares are currently trading at 14x TTM sales, well ahead of the GICS Health Care sector peer median of 4.45x. In addition, AXNX looks to be richly priced at 7.3x book value, again far in front of the peer's 2.16x multiple. However, the market has AXNX priced at ~13.3x forward sales, which, we believe, suggests the investors are pricing in an above-sector result for the company at the topline for the coming 12 months. We estimate FY23 sales of $317mm for the company, and at 13x this estimate sets a price target of $84, roughly 18% return potential from the current market price.
Seeking Alpha • Aug 03

Axonics prices stock offering of 1.75M shares

Axonics (NASDAQ:AXNX) priced its earlier announced underwritten public offering of 1.75M shares. Underwriters granted 30-day option to purchase up to 262.5K additional shares. Offer is expected to close on Aug.5, 2022. Net proceeds to be used working capital and general corporate purposes, including a potential $35M milestone payment in connection with its earlier announced and completed acquisition of Contura. Shares trading 3.1% down premarket.
Analyseartikel • Aug 02

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • May 30

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

Axonics is a high-growth medical device play with strong revenue growth drivers. The company’s rechargeable SNM system generates the vast majority of its sales. Long-term investors can buy the company’s shares during pullbacks to maximize their gain.
Analyseartikel • Apr 19

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analyse CEO-vergoeding

Hoe is Ray Cohen's beloning veranderd ten opzichte van Axonics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$7mUS$800k

-US$6m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$5mUS$750k

-US$60m

Sep 30 2022n/an/a

-US$76m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$6mUS$625k

-US$80m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$1mUS$527k

-US$55m

Sep 30 2020n/an/a

-US$66m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$6mUS$500k

-US$80m

Sep 30 2019n/an/a

-US$67m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$1mUS$430k

-US$32m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$25m

Mar 31 2018n/an/a

-US$20m

Dec 31 2017US$605kUS$430k

-US$18m

Compensatie versus markt: De totale vergoeding ($USD 7.37M ) Ray } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.92M ).

Compensatie versus inkomsten: De vergoeding van Ray is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ray Cohen (65 yo)

11.1yrs
Tenure
US$7,369,375
Compensatie

Mr. Raymond W. Cohen, also known as Ray, is Independent Director of Kestra Medical Technologies, Inc. from July 2024. Mr. Cohen is Venture Advisor of Andera Partners. He focuses on Life Sciences.He works...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Raymond Cohen
CEO & Director11.1yrsUS$7.37m0.57%
$ 20.6m
Kari Keese
Chief Financial Officer1.1yrsUS$3.76m0.079%
$ 2.8m
Rinda Sama
Chief Operating Officer6.3yrsUS$3.04m0.17%
$ 6.0m
John Woock
Executive VP6.4yrsUS$3.26m0.15%
$ 5.5m
Alfred Ford
Chief Commercial Officer7yrsUS$2.94m0.085%
$ 3.1m
Guangqiang Jiang
Chief Technology Officer11.1yrsgeen gegevensgeen gegevens
Neil Bhalodkar
Vice President of Investor Relationsno datageen gegevensgeen gegevens
Aaron Pettit
General Counsel & Chief Compliance Officerno datageen gegevensgeen gegevens
Michael Williamson
Senior VPno datageen gegevensgeen gegevens
Karen Noblett
Chief Medical Officer7.1yrsUS$651.40k0.067%
$ 2.4m
Prabodh Mathur
Chief Product Development Officer10.5yrsgeen gegevensgeen gegevens
7.0yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van AXNX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Raymond Cohen
CEO & Director11.1yrsUS$7.37m0.57%
$ 20.6m
Michael Carrel
Independent Chairman5.8yrsUS$250.00k0.035%
$ 1.3m
Nancy Snyderman
Independent Director5.6yrsUS$222.50k0.039%
$ 1.4m
David Demski
Independent Director3.8yrsUS$210.00k0.019%
$ 672.2k
Robert McNamara
Independent Director6yrsUS$227.50k0.029%
$ 1.0m
Jane Kiernan
Independent Director5.6yrsUS$225.00k0.039%
$ 1.4m
Esteban Lopez
Independent Director3.3yrsUS$215.00k0.013%
$ 464.8k
5.6yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AXNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/11/14 04:31
Aandelenkoers aan het einde van de dag2024/11/14 00:00
Inkomsten2024/09/30
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Axonics, Inc. wordt gevolgd door 7 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Travis SteedBarclays
Travis SteedBofA Global Research
Christopher PasqualeGuggenheim Securities, LLC